Revolutionary hair growth therapies
Triple Hair is a clinical-stage Canadian biotechnology company specialized in the development of innovative treatments for alopecia.
Featuring our drug-free hair growth formula Therapy-16 as the RIZN Hair Density Spray
RIZN is a drug-free and prescription-free product line developed to stop hair shedding and induce hair regrowth in men with mild to moderate hair loss.
Discover Plenty Natural
Featuring our drug-free hair growth formula Therapy-16 as the Plenty Hair Densifying Spray
A brand dedicated to supporting women with mild to moderate alopecia in their journey towards healthier hair.
This triple combination therapy works synergistically to encourage optimal hair regrowth in men with androgenic alopecia. Significant regrowth was observed among participants in the clinical trials.
Over-the-counter natural product
This clinically proven, natural combination formula beats market-leading, synthetic formulas and is the perfect choice for men and women looking to prevent hair loss and boost hair growth, thickness, and pigmentation.
Therapy-16 is now available as:
Inspired by the life experience of our founder, Dr. Houfar Sekhavat, we are dedicated to restoring the confidence of patients suffering from hair loss by providing them with safe and effective products. Our approach is based on sharing and collaborating with the scientific community. We know that what we discover can have a positive impact on the lives of millions of people, which is what drives us to give the best of ourselves every day.
While the company is currently well funded, we are always seeking funds to secure our ongoing and future research activities. If you are interested in investing in Triple Hair, get in touch with our team to learn more about our current round of financing.
Our highly skilled professionals have formulated the best-performing hair loss therapies to date. Thanks to their innovative approach to product development and strong work ethic, the company has reached its goal: design products that really work.
The hair loss
market in 2020
20% of the world's population suffers from hair loss (alopecia).
Hair loss treatments are a US$8.5 billion industry.
80 million people suffer from hair loss in the United States alone.
The Triple Hair team is set to initiate Phase III clinical trials in Canada and the United States for their TH-07 triple combination therapy. The trial will involve double-blinded, randomized, placebo-controlled, parallel-group tests, will take place over a year, and be conducted in multiple Canadian & U.S. sites.
Corporate and scientific news
Subscribe to our mailing list